Skip to main content
Clinical Trials/JPRN-jRCT1080220031
JPRN-jRCT1080220031
Unknown
Phase 4

Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval)

DAIICHI SANKYO COMPANY, LIMITED0 sitesSeptember 6, 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
[Spinal cord Origin] Spinal cord Injury, Multiple sclerosis, Spinocerebellar degeneration, Circulatory disorder of the spinal, Ossification of the posterior longitudinal ligament [Cerebral Origin] Cerebral palsy, Traumatic head injury
Sponsor
DAIICHI SANKYO COMPANY, LIMITED
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 6, 2005
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patient meeting the criteria for inclusion, who intend to continue the treatment with intrathecal baclofen using the implanted pump system after approval of NDA. The written informed consent by the patients or the legal representative is a must.
  • \[Criteria for inclusion]
  • 1\) Patient effective to the intrathecal baclofen therapy at the long term safety clinical trial(phase 3\), and is judged as no safety issue by the doctor.
  • 2\) Patient who can be regularly followed during clinical trial.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials